Further key findings from the report suggest:
Mammalian cell line-based bioproduction system dominated the share in 2016 in terms of revenue
generation
This can be attributed to the presence of substantial number of mammalian-based manufacturing
platforms offered by market leaders such as Lonza, Samsung BioLogics, WuXi Biologics
CMOs are providing wide range of services for entire chain of biopharmaceutical manufacturing
process, consequently held the largest share
Growing R&D investment in bioproduction is the high impact rendering factor for the growth of CROs
Robust biologics pipeline and high production cost of biologics have contributed to the largest share of
biologics outsourcing
Monoclonal antibodies accounted for significant share in 2016 owing to the huge success rate of MAbs
for disease treatment
North America is home to large number of biopharmaceutical manufacturing entities, which in turn,
have resulted into large share of this region
Being a lower wage country, China and India are expected to be fastest growing regional market
Several global companies are translocating their business to Asia Pacific owing to low manufacturing
costs in Asian countries
Boehringer Ingelheim GmbH, Lonza, Samsung BioLogics, Patheon, FUJIFILM Diosynth Biotechnologies
U.S.A., Inc. are some of the major companies operating in this space
Request A Sample copy of This Report @
https://www.hexareports.com/report/biopharmaceutical-cmo-and-cro-market/request-sample
Table Of Content
Chapter 1 Research Methodology
1.1. Information Procurement
1.2. Data Analysis
1.3. Market Formulation & Validation
1.4. Approaches for Market Estimation
Chapter 2 Executive Summary
2.1 Market Snapshot
Chapter 3 Market Variables, Trends & Scope
3.1 Market Segmentation &Scope
Follow Us: